Biotech Fund Beating 92% of Peers Sees More M&A Deals to Come

A rebound in global biotech deals this year looks set to accelerate as big pharmaceutical companies seek new sources of revenue, according to a top-performing fund with a track record of identifying acquisition targets....

Redirecting to full article...